NCT04788407 (PENTZ) is a Phase 4 clinical trial of Nitazoxanide in Covid19, sponsored by Fundación Huésped.

Who is sponsoring NCT04788407?

NCT04788407 is sponsored by Fundación Huésped.

What drugs are being tested in NCT04788407?

Interventions in NCT04788407: Nitazoxanide, Placebo.

What condition does NCT04788407 study?

NCT04788407 studies Covid19, SARS-CoV-2 Infection, Households Contacts.

Is NCT04788407 still recruiting?

NCT04788407 is currently status unknown. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT04788407: PENTZ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

Status unknown Phase 4 Last updated 2 July 2021

What this trial tests

Phase 4 trial testing Nitazoxanide in Covid19 in 456 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	Fundación Huésped
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	456
Start date	1 December 2020
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	1 location across Argentina

Drugs / interventions tested

Nitazoxanide (NITAZOXANIDE) — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →
SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
Households Contacts — all drugs for Households Contacts →

Sponsor

Fundación Huésped — full company profile →

Who can join

Adults 18 to 65, any sex, with Covid19 or SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 500 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in household contacts of patients diagnosed with the disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Prophylactic Treatments for COVID-19.
Ben-Zuk N, Dechtman ID, Henn I, Weiss L, et al · · 2021 · cited 9× · PMID 34372498 · DOI 10.3390/v13071292
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).
Smith T, Hoyo-Vadillo C, Adom AA, Favari-Perozzi L, et al · · 2022 · cited 6× · PMID 35869526 · DOI 10.1186/s13063-022-06533-0

Verify or expand the search:

Other trials of Nitazoxanide

Trials testing the same drug.

NCT06993974 — Nitazoxanide in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07086937 — Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children · NA · completed
NCT06010992 — Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus · Phase 2 · unknown
NCT05368935 — Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects · Phase 1 · completed
NCT05116826 — Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients · Phase 1 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Fundación Huésped trials

Trials by the same sponsor.

NCT07357584 — Efficacy and Safety of Doravirine in the Rapid Initiation · Phase 4 · not yet recruiting
NCT06588257 — Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study · Phase 4 · active not recruiting
NCT05293223 — Phase IIB Study of Recombinant Novel Coronavirus Vaccine · Phase 2 · completed
NCT05005156 — Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV · Phase 2 · completed
NCT04880395 — Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04788407 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Huésped
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04788407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing